Viatris Inc.

VTRS

US92556V1061

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
11.84 ^USD	+4.04%		+8.72%	+9.33%

03/07	Viatris Divests Over-the-Counter Business to Cooper Consumer Health	MT
03/07	Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc..	CI

Mylan N.V. 's Equity Buyback announced on November 16, 2015 has closed with 23,490,867 shares, representing 4.44% for $1,000 million.

January 09, 2018

The company closed its plan on January 9, 2018.

Latest news about Viatris Inc.

Viatris Divests Over-the-Counter Business to Cooper Consumer Health	03/07	MT
Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc..	03/07	CI
Viatris : Mylan No Longer Subject of Antitrust Investigation by Justice Dept	02/07	DJ
Viatris Says US Department of Justice's Antitrust Division No Longer Considers Mylan Subject of Investigation	02/07	MT
US DOJ drops Viatris unit Mylan from industry-wide antitrust probe	02/07	RE
US DOJ informs Viatris' Mylan is no longer part of antitrust investigation	02/07	RE
European Commission Conditionally Approves Cooper-Viatris Deal	27/06	MT
Transcript : Viatris Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM	11/06
Transcript : Viatris Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 08:00 AM	06/06
Viatris Inc. Appoints Rogerio Vivaldi Coelho to Board of Directors	03/06	CI
IQuest Enterprises Private Limited acquired API operations of Viatris in India.	03/06	CI
Transcript : Viatris Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM	14/05
Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing	11/05	MT
UBS Trims Viatris Price Target to $12 From $13, Maintains Neutral Rating	10/05	MT
Transcript : Viatris Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022.	09/05	CI
Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024	09/05	CI
Viatris Inc. Revises Earnings Guidance for the Year 2024	09/05	CI
Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced	09/05	MT
(VTRS) VIATRIS Forecasts Fiscal Year 2024 Revenue Range $14.98B - $15.48B	09/05	MT
Earnings Flash (VTRS) VIATRIS Posts Q1 Revenue $3.66B, vs. Street Est of $3.69B	09/05	MT
Earnings Flash (VTRS) VIATRIS Reports Q1 EPS $0.67, vs. Street Est of $0.67	09/05	MT
Viatris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
China trade heats up, UK rates in view	09/05	RE
Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	18/04	MT

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Companyâs ARV franchise. The Companyâs portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Viatris Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.84 USD

Average target price

12.27 USD

Spread / Average Target

+3.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VIATRIS INC.	+9.33%	14.1B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.36%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.49%	247B
NOVARTIS AG	+14.94%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Viatris Inc.

Equities

VTRS

US92556V1061

Pharmaceuticals

Mylan N.V. 's Equity Buyback announced on November 16, 2015 has closed with 23,490,867 shares, representing 4.44% for $1,000 million.

Latest news about Viatris Inc.

Chart Viatris Inc.

Company Profile

Income Statement Evolution

Ratings for Viatris Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals